Jak1 - Janus kinase 1 Gene

Mus musculus

Also known as BAP004; C130039L05Rik

Gene ID: 16451 | Gene type: protein coding

About Jak1

Chromosome 4: 101,009,564-101,122,479 reverse strand.GRCm39:CM000997.3

This gene has 8 transcripts (splice variants), 238 orthologues, 32 paralogues and is associated with 66 phenotypes. Ubiquitous expression in thymus adult (RPKM 28.5), spleen adult (RPKM 26.3) and 28 other tissues.

Summary

Enables growth hormone receptor binding activity and protein tyrosine kinase activity. Acts upstream of or within several processes, including cell surface receptor signaling pathway; cellular response to cytokine stimulus; and positive regulation of receptor signaling pathway via STAT. Predicted to be located in cytoplasm and nucleus. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; hemolymphoid system gland; and liver and biliary system. Used to study systemic lupus erythematosus. Human ortholog(s) of this gene implicated in T-cell acute lymphoblastic leukemia; colorectal cancer; hepatocellular carcinoma; ovarian cancer; and pancreatic adenocarcinoma. Orthologous to human JAK1 (Janus kinase 1). [provided by Alliance of Genome Resources, Apr 2022]

Jak1 Products(2)

mRNA	Protein	Name
NM_146145.2	NP_666257.2	tyrosine-protein kinase JAK1 isoform 1
NM_013567.1	NP_038595.1	tyrosine-protein kinase JAK1 isoform 2

Jak1 Protein Structure

FERM_F1

FERM_F2

FERM_C_JAK1

SH2_Jak1

PTK_Jak1_rpt1

PTKc_Jak1_rpt2

0
200
400
600
800
1000
1153 a.a.

Protein Preferred Names

Protein Names

tyrosine-protein kinase JAK1

JAK-1

Related Agents

Approval

Bioactive Molecules (19)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-50856	Ruxolitinib	Inhibitor	99.99%	Yes
HY-40354	Tofacitinib	Inhibitor	99.99%	Yes
HY-117287	Deucravacitinib	Inhibitor	99.87%	Yes
HY-15315	Baricitinib	Inhibitor	99.97%	Yes
HY-19569	Upadacitinib	Inhibitor	99.98%	Yes
HY-50858	Ruxolitinib phosphate	Inhibitor	99.98%	Yes
HY-16379	Pacritinib	Inhibitor	99.93%	Yes
HY-40354A	Tofacitinib citrate	Inhibitor	99.98%	Yes
HY-18300	Filgotinib	Inhibitor	99.68%	Yes
HY-107429	Abrocitinib	Inhibitor	99.26%	Unkown
HY-19568	Peficitinib	Inhibitor	99.43%	Yes
HY-15315A	Baricitinib phosphate	Inhibitor	99.91%	Yes
HY-109053	Delgocitinib	Inhibitor	99.87%	Unkown
HY-13577A	Oclacitinib maleate	Inhibitor	99.63%	Unkown
HY-13577	Oclacitinib	Inhibitor	99.23%	Unkown
HY-19569A	Upadacitinib tartrate tetrahydrate	Inhibitor	/	Unkown
HY-16379A	Pacritinib hydrochloride	Inhibitor	/	Unkown
HY-18300A	Filgotinib maleate	Inhibitor	/	Unkown
HY-50859	Ruxolitinib sulfate	Inhibitor	/	Unkown

Clinical Phase

Bioactive Molecules (20)

Cat. No.	Product Name	Effect	Purity	Phase
HY-10961	Momelotinib	Inhibitor	99.37%	Phase 3
HY-16997	Itacitinib	Inhibitor	99.97%	Phase 3
HY-15999	Cerdulatinib	Inhibitor	98.96%	Phase 3
HY-12469	Decernotinib	Inhibitor	99.67%	Phase 3
HY-10962	Momelotinib sulfate	Inhibitor	98.06%	Phase 3
HY-112724	Ivarmacitinib	Inhibitor	99.82%	Phase 3
HY-16997A	Itacitinib adipate	Inhibitor	99.18%	Phase 3
HY-15999A	Cerdulatinib hydrochloride	Inhibitor	99.89%	Phase 3
HY-50856S	Deuruxolitinib	Inhibitor	99.18%	Phase 3
HY-10963	Momelotinib Mesylate	Inhibitor	/	Phase 3
HY-15270	BMS-911543	Inhibitor	98.53%	Phase 2
HY-112708A	Brepocitinib P-Tosylate	Inhibitor	99.86%	Phase 2
HY-107361	Golidocitinib	Inhibitor	99.75%	Phase 2
HY-19631A	Ilginatinib	Inhibitor	99.94%	Phase 2
HY-16755	Solcitinib	Inhibitor	99.73%	Phase 2
HY-112708	Brepocitinib	Inhibitor	98.64%	Phase 2
HY-19631B	Ilginatinib hydrochloride	Inhibitor	≥98.0%	Phase 2
HY-19631	Ilginatinib maleate	Inhibitor	99.87%	Phase 2
HY-10193	AZD-1480	Inhibitor	99.56%	Phase 1
HY-126294	Londamocitinib	Inhibitor	98.98%	Phase 1

Pre-clinical Phase

Bioactive Molecules (45)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-W063968	RO8191	Activator	≥99.0%	Unkown
HY-14435	Pyridone 6	Inhibitor	98.13%	Unkown
HY-100895	SAR-20347	Inhibitor	97.12%	Unkown
HY-151385	VVD-118313	Inhibitor	99.75%	Unkown
HY-14722	NVP-BSK805	Inhibitor	99.89%	Unkown
HY-12589	ZM39923 hydrochloride	Inhibitor	98.19%	Unkown
HY-14722A	NVP-BSK805 dihydrochloride	Inhibitor	99.36%	Unkown
HY-151262	JAK-IN-23	Inhibitor	98.90%	Unkown
HY-130247	JAK2/FLT3-IN-1	Inhibitor	99.79%	Unkown
HY-131906	JAK2-IN-7	Inhibitor	99.15%	Unkown
HY-130247A	JAK2/FLT3-IN-1 TFA	Inhibitor	99.77%	Unkown
HY-108264	TCS 21311	Inhibitor	99.18%	Unkown
HY-139423	JAK1-IN-8	Inhibitor	≥95.0%	Unkown
HY-120469	2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	Inhibitor	98.78%	Unkown
HY-19544	JAK3-IN-1	Inhibitor	99.23%	Unkown
HY-13961	GLPG0634 analog	Inhibitor	98.58%	Unkown
HY-151385A	(R,R)-VVD-118313	Inhibitor	99.54%	Unkown
HY-111750	JAK-IN-3	Inhibitor	98.92%	Unkown
HY-116505	JAK1-IN-4	Inhibitor	/	Unkown
HY-W394903	GS-829845	Inhibitor	99.91%	Unkown
HY-14722C	NVP-BSK805 trihydrochloride	Inhibitor	/	Unkown
HY-152080	TUL01101	Inhibitor	/	Unkown
HY-156409	ABBV-712	Inhibitor	/	Unkown
HY-143444	JAK-IN-20	Inhibitor	/	Unkown
HY-139649	Ten01	Inhibitor	/	Unkown
HY-100849	JAK 3i	Inhibitor	/	Unkown
HY-147975	JAK3-IN-12	Inhibitor	/	Unkown
HY-161259	JAK-IN-36	Inhibitor	/	Unkown
HY-146727	JAK3-IN-11	Inhibitor	/	Unkown
HY-15814	HG-7-85-01	Inhibitor	99.94%	Unkown
HY-150720	TYK2-IN-12	Inhibitor	/	Unkown
HY-144440	JAK1-IN-9	Inhibitor	/	Unkown
HY-108342	PF-00956980	Inhibitor	/	Unkown
HY-149283	JAK/HDAC-IN-2	Inhibitor	/	Unkown
HY-162248	JAK1/2-IN-1	Inhibitor	/	Unkown
HY-153440	JAK-IN-25	Inhibitor	98.44%	Unkown
HY-154994	JAK-IN-30	Inhibitor	/	Unkown
HY-148060	JAK-IN-21	Inhibitor	99.72%	Unkown
HY-153566	JAK1-IN-10	Inhibitor	/	Unkown
HY-157121	JAK-IN-34	Inhibitor	/	Unkown
HY-161139	JAK1-IN-14	Inhibitor	/	Unkown
HY-147754	JAK3/BTK-IN-6	Inhibitor	/	Unkown
HY-149296	JAK1-IN-12	Inhibitor	/	Unkown
HY-143885	JAK1/TYK2-IN-3	Inhibitor	/	Unkown
HY-12589A	ZM39923	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Jak1	NCBI	NCBI:3716

Name
Email *

	Sorry, but the email address you supplied was invalid.